PT - JOURNAL ARTICLE AU - Mollenhauer, Brit AU - Li, Juan AU - Schade, Sebastian AU - Weber, Sandrina AU - Trenkwalder, Claudia AU - Concha-Marambio, Luis AU - Tomlinson, Julianna J. AU - , AU - Schlossmacher, Michael G. TI - Persistent Hyposmia as Surrogate for α-Synuclein-Linked Brain Pathology AID - 10.1101/2023.12.19.23300164 DP - 2023 Jan 01 TA - medRxiv PG - 2023.12.19.23300164 4099 - http://medrxiv.org/content/early/2023/12/21/2023.12.19.23300164.short 4100 - http://medrxiv.org/content/early/2023/12/21/2023.12.19.23300164.full AB - Impaired olfaction can be associated with neurodegenerative disorders. We examined odor identification in newly diagnosed patients with parkinsonism and those at increased risk, measured olfactory performances longitudinally, and juxtaposed results to cerebrospinal fluid (CSF) values. Using Sniffin’-Sticks-Identification Tests (SST-ID), we examined 312 age-matched individuals at a German center, including: 126 with Parkinson disease (PD), 109 healthy controls, 25 with other neurodegenerative disorders and 52 with a REM-sleep behavior disorder (RBD). As expected, PD patients had significantly lower SST-ID scores than controls. Scent identification by subjects with other neurodegenerative diseases fell between those with PD and healthy individuals. Those with isolated RBD, who subsequently converted to PD or dementia, had lower baseline scores than non-converters. When monitoring olfaction in participants up to a decade, we saw small group differences in progression rates for hyposmia. However, these variations were insignificant after controlling for age, sex and length of intervals between testing. When analyzing participants’ sense of smell versus several CSF biomarkers linked to neurodegeneration, we found no correlation with SST-ID scores. However, the means for normalized concentrations of α-synuclein, total tau, phosphorylated tau and amyloid-β peptide42 were reduced in PD. We also identified significant age- and sex-linked differences in CSF values. Finally, we compared olfaction to the results of a validated α-synuclein ‘Seed Amplification Assay’ (SAA) using CSF. We found that hyposmia strongly correlated with a positive CSF α-synuclein SAA-test. We conclude that chronically impaired olfaction in older adults is strongly associated with a positive α-synuclein SAA-test from CSF but not with the concentrations of several, neuropathologically relevant CSF markers. We posit that simple-to-administer, quantitative smell tests could serve as inexpensive screening tools in future population studies for the identification of α-synuclein-related brain disorders, including Parkinson’s during its premotor phase.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded in part by Aligning Science Across Parkinson's [Grant ID: ASAP-020625] administered by the Michael J. Fox Foundation for Parkinson's Research (MJFF) and by the Parkinson Research Consortium Ottawa.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Investigational Review Board of Landesaerztekammer Hesse in Frankfurt, Germany (FF89/2008) and the Regulatory Ethics Board of The Ottawa Hospital in Ottawa, Canada (20180010-01H) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData can be accessed via zenodo (https://zenodo.org/records/10222976). https://zenodo.org/records/10222976